MDACC Study No:2013-0433 ( NCT No: NCT01880437)
Title:A Phase IB/II Study to Evaluate the Safety and Efficacy of Vismodegib in Relapsed/Refractory Acute Myelogenous Leukemia (AML) and Relapsed/Refractory High-Risk Myelodysplastic Syndrome (MDS)
Principal Investigator:Jorge Cortes
Treatment Agent:Vismodegib
Study Status:Closed
Study Description:The goal of this clinical research study is to learn if vismodegib when given
with and /or without Cytostar (cytarabine) can help to control relapsed or
refractory AML or MDS. The safety of this drug will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase I/Phase II
Treatment Agents:Vismodegib
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:F. Hoffmann-La Roche Ltd
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Jorge Cortes
For Clinical Trial Enrollment:713-794-5783
For General Questions about Clinical Trials:1-877-MDA-6789

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults